サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1316874

抗体薬物複合体市場：作用機序、薬剤、技術、用途、エンドユーザー別-2023～2030年の世界予測

Antibody Drug Conjugate Market by Mechanism of Action, Drugs, Technology, Application, End User - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 192 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
抗体薬物複合体市場：作用機序、薬剤、技術、用途、エンドユーザー別-2023～2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 192 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗体薬物複合体の世界市場は、2023年に58億9,128万米ドル、CAGR16.19%で大きく成長し、2030年には168億6,347万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の抗体薬物複合体市場を評価するために不可欠です。事業戦略や製品満足度などの主要指標を検証することで、ベンダーの包括的な評価を提供し、ユーザーが特定のニーズに基づいて情報に基づいた意思決定を行えるようにします。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客ベース、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.抗体薬物複合体の世界市場規模および予測は？

2.予測期間中、世界の抗体薬物複合体市場を形成するCOVID-19の阻害要因と影響は？

3.抗体薬物複合体の世界市場において予測期間中に投資すべき製品/セグメント/用途/分野は？

4.抗体薬物複合体の世界市場における競争戦略は？

5.抗体薬物複合体の世界市場における技術動向と規制の枠組みは？

6.抗体薬物複合体の世界市場における主要ベンダーの市場シェアは？

7.抗体薬物複合体の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中でガンの有病率が増加
      • 臨床試験活動の成長と堅牢な製品パイプライン
      • がん治療を促進する政府の支援と取り組み
    • 抑制要因
      • 抗体薬物複合体の製造コストが高い
    • 機会
      • バイオ医薬品の研究開発への投資の増加
      • 抗体薬物複合体開発に先進技術を活用
    • 課題
      • 抗体薬物複合体の下流処理に関連する課題
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 抗体薬物複合体市場：作用機序別

  • イントロダクション
  • CD30抗体
  • ErbB2抗体

第7章 抗体薬物複合体市場：薬剤別

  • イントロダクション
  • アドセトリス
  • カドサイラ

第8章 抗体薬物複合体市場：技術別

  • イントロダクション
  • 切断可能リンカー
  • リンカーレス
  • 切断不可能リンカー

第9章 抗体薬物複合体市場：用途別

  • イントロダクション
  • 血液がん
  • 乳がん
  • 白血病
  • リンパ腫
  • 多発性骨髄腫
  • 尿路上皮がんと膀胱がん

第10章 抗体薬物複合体市場：エンドユーザー別

  • イントロダクション
  • 学術研究機関
  • バイオ医薬品企業
  • バイオテクノロジー企業
  • 病院
  • がん専門センター

第11章 南北アメリカの抗体薬物複合体市場

  • イントロダクション
  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第12章 アジア太平洋地域の抗体薬物複合体市場

  • イントロダクション
  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第13章 欧州・中東・アフリカの抗体薬物複合体市場

  • イントロダクション
  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第14章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ分析：主要企業別

第15章 掲載企業一覧

第16章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ANTIBODY DRUG CONJUGATE MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBODY DRUG CONJUGATE MARKET SIZE, 2022 VS 2030
  • FIGURE 3. ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2022 VS 2030 (%)
  • FIGURE 5. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2022 VS 2030 (%)
  • FIGURE 6. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2022 VS 2030 (%)
  • FIGURE 7. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
  • FIGURE 8. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2022 VS 2030 (%)
  • FIGURE 9. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 10. ANTIBODY DRUG CONJUGATE MARKET DYNAMICS
  • FIGURE 11. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 20. ANTIBODY DRUG CONJUGATE MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 21. ANTIBODY DRUG CONJUGATE MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. ANTIBODY DRUG CONJUGATE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CD30 ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ERBB2 ANTIBODIES , BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 8. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ADCETRIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY KADCYLA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 11. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE LINKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKERLESS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON-CLEAVABLE LINKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY UROTHELIAL CANCER & BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SPECIALIZED CANCER CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. ANTIBODY DRUG CONJUGATE MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 237. ANTIBODY DRUG CONJUGATE MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 238. ANTIBODY DRUG CONJUGATE MARKET LICENSE & PRICING
目次
Product Code: MRR-657F2A76F4F8

The Global Antibody Drug Conjugate Market is forecasted to grow significantly, with a projected USD 5,891.28 million in 2023 at a CAGR of 16.19% and expected to reach a staggering USD 16,863.47 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Antibody Drug Conjugate Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Antibody Drug Conjugate Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Mechanism of Action, market is studied across CD30 Antibodies and ErbB2 Antibodies. The ErbB2 Antibodies is projected to witness significant market share during forecast period.

Based on Drugs, market is studied across Adcetris and Kadcyla. The Adcetris is projected to witness significant market share during forecast period.

Based on Technology, market is studied across Cleavable Linker, Linkerless, and Non-Cleavable Linker. The Non-Cleavable Linker is projected to witness significant market share during forecast period.

Based on Application, market is studied across Blood Cancer, Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma, and Urothelial Cancer & Bladder Cancer. The Multiple Myeloma is projected to witness significant market share during forecast period.

Based on End User, market is studied across Academic Research Institutes, Biopharmaceutical Companies, Biotechnology Companies, Hospitals, and Specialized Cancer Centers. The Academic Research Institutes is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Antibody Drug Conjugate Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Antibody Drug Conjugate Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Antibody Drug Conjugate Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Antibody Drug Conjugate Market?

4. What is the competitive strategic window for opportunities in the Global Antibody Drug Conjugate Market?

5. What are the technology trends and regulatory frameworks in the Global Antibody Drug Conjugate Market?

6. What is the market share of the leading vendors in the Global Antibody Drug Conjugate Market?

7. What modes and strategic moves are considered suitable for entering the Global Antibody Drug Conjugate Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Antibody Drug Conjugate Market, by Mechanism of Action, 2022 vs 2030
  • 4.3. Antibody Drug Conjugate Market, by Drugs, 2022 vs 2030
  • 4.4. Antibody Drug Conjugate Market, by Technology, 2022 vs 2030
  • 4.5. Antibody Drug Conjugate Market, by Application, 2022 vs 2030
  • 4.6. Antibody Drug Conjugate Market, by End User, 2022 vs 2030
  • 4.7. Antibody Drug Conjugate Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer worldwide
      • 5.1.1.2. Growth in clinical trial activities and robust product pipeline
      • 5.1.1.3. Government support and initiatives encouraging cancer treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High manufacturing cost of ADC
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investment in biopharma R&D
      • 5.1.3.2. Use of advanced technologies for developing ADC
    • 5.1.4. Challenges
      • 5.1.4.1. Challenges related to downstream processing of antibody-drug conjugate
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Antibody Drug Conjugate Market, by Mechanism of Action

  • 6.1. Introduction
  • 6.2. CD30 Antibodies
  • 6.3. ErbB2 Antibodies

7. Antibody Drug Conjugate Market, by Drugs

  • 7.1. Introduction
  • 7.2. Adcetris
  • 7.3. Kadcyla

8. Antibody Drug Conjugate Market, by Technology

  • 8.1. Introduction
  • 8.2. Cleavable Linker
  • 8.3. Linkerless
  • 8.4. Non-Cleavable Linker

9. Antibody Drug Conjugate Market, by Application

  • 9.1. Introduction
  • 9.2. Blood Cancer
  • 9.3. Breast Cancer
  • 9.4. Leukemia
  • 9.5. Lymphoma
  • 9.6. Multiple Myeloma
  • 9.7. Urothelial Cancer & Bladder Cancer

10. Antibody Drug Conjugate Market, by End User

  • 10.1. Introduction
  • 10.2. Academic Research Institutes
  • 10.3. Biopharmaceutical Companies
  • 10.4. Biotechnology Companies
  • 10.5. Hospitals
  • 10.6. Specialized Cancer Centers

11. Americas Antibody Drug Conjugate Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Antibody Drug Conjugate Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Antibody Drug Conjugate Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. FPNV Positioning Matrix
  • 14.2. Market Share Analysis, By Key Player
  • 14.3. Competitive Scenario Analysis, By Key Player

15. List of Company Mentioned

16. Appendix

  • 16.1. Discussion Guide
  • 16.2. License & Pricing